Karnataka Govt Unveils 3-Year Plan to Strengthen Advanced Healthcare Access

The Karnataka government has declared a grand three-year program to revamp the state's healthcare network by setting up super-specialty hospitals, trauma centres, and cancer treatment units in all 31 districts of the state.

India to Curb Open Market Access to Key TB Drugs Amid Resistance Concerns

The Indian government is set to limit open market access to key anti-tuberculosis medicines in order to contain misuse of critical medications that could lead to the emergence of drug resistance. This measure comes in light of the expiry of...

AstraZeneca Expands Bengaluru Hub to Boost AI and R&D Innovation

AstraZeneca, a biopharmaceutical company, announced on Thursday that it had invested Rs 166 crore to expand its global center in Bengaluru, adding 400 positions to support AI innovation, global services, and research & development.

India's First TREAT Program for Kidney Transplant Launched by Fortis

In yet another clinical milestone, Fortis Hospital, Bannerghatta Road, Bengaluru has advanced its robot-aided infrastructure with the launch of the TREAT program

Lupin Launches Prucalopride Tablets to Expand GI Drug Portfolio

Lupin Ltd, the world's largest Indian pharma company, has declared US commercial availability of Prucalopride tablets with strengths of 1 mg and 2 mg.

Study Flags Quality Failures in Indian-Made Chemotherapy Drugs

A new study has shown that many widely used generic chemotherapy medicines around the world have failed quality testing. This raises serious doubts about the safety and efficacy of cancer therapy in more than 100 countries. The affected drugs...

Aurobindo's CuraTeQ Gets UK MHRA Nod for Biosimilar Dyrupeg

Hyderabad-based Aurobindo Pharma has made a milestone in its biosimilar growth plans, when its subsidiary CuraTeQ Biologics s.r.o. received clearance by the UK's Medicines and Healthcare products Regulatory Agency

Indian Pharma Charts Clear Path to Meet Revised Schedule M Rules

As global pressure and expectations increase with the drug quality, Indian pharma has to become intolerant to non-compliance with Good Manufacturing Practice (GMP), stressed Mahantesh Wali, Regulatory Affairs Head at Maiva Pharma.

Govt Proposes Licence Suspension for Drugs Failing Quality Tests

The Union Health Ministry is looking to tighten drug quality regulations by proposing to immediately suspend manufacturing licenses of pharmaceutical companies for drugs that fail government lab testing. The change follows a recommendation from...

Pharmexcil Appoints Advisors to Strengthen Export Regulatory Support

Pharmaceuticals Export Promotion Council of India (Pharmexcil) has assigned two honorary advisors to provide assistance to export pharmaceutical producers with regulatory issues surrounding Foreign Trade Policy (FTP) permitting and other matters...

© 2025 India Pharma Outlook. All Rights Reserved.